Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort: reply

Affiliations

¹ Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK.
² Department of Medicine, University Malaya, Kuala Lumpur, Malaysia.
³ Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich.
⁴ Department of Pharmacology, University of Bath, Bath, UK.

Fariz Yahya et al. Rheumatol Adv Pract. 2018.

. 2018 Oct 18;2(2):rky037.

doi: 10.1093/rap/rky037. eCollection 2018.

¹ Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK.
² Department of Medicine, University Malaya, Kuala Lumpur, Malaysia.
³ Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich.
⁴ Department of Pharmacology, University of Bath, Bath, UK.

No abstract available

References

1. Al Arashi W, Hensor EM, Gaffney K. et al. Comment on: tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort. Rheumatology Advances in Practice 2018; doi:10.1093/rap/rky036. - PMC - PubMed
1. Yahya F, Gaffney K, Hamilton L. et al. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort. Rheumatology 2018;57:619–24. - PubMed
1. Zeboulon N, Dougados M, Gossec L.. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67:955–9. - PubMed
1. Kim TJ, Kim TH.. Clinical spectrum of ankylosing spondylitis in Korea. Joint Bone Spine 2010;77:235–40. - PubMed